UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000047881
Receipt number R000054591
Scientific Title Feasibility Study of Preoperative DCF Therapy in Esophageal Cancer
Date of disclosure of the study information 2022/09/01
Last modified on 2022/10/13 19:30:58

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Feasibility Study of Preoperative DCF Therapy in Esophageal Cancer

Acronym

FEVER trial

Scientific Title

Feasibility Study of Preoperative DCF Therapy in Esophageal Cancer

Scientific Title:Acronym

FEVER trial

Region

Japan


Condition

Condition

Esophageal cancer

Classification by specialty

Gastroenterology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy and safety of preoperative chemotherapy for esophageal cancer in DCF therapy

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Phase II


Assessment

Primary outcomes

Incidence of febrile neutropenia

Key secondary outcomes

Progression Free Survival
Overall Survival
Objective Response Rate
pathological Complete Response
R0 resection rate
Adverse Event
Suture failure rate
Postoperative pneumonia rate


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

DCF therapy

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1 Endoscopic biopsy of the primary esophageal lesion has been histologically diagnosed as either squamous cell carcinoma or adenosquamous carcinoma
2 Clinical stage T1N1to3M0, T2to3N0to3M0 according to the UICC TNM 8th edition
3 18 years or older
4 Patient can receive initial DCF therapy without dose reduction
5 Performance status is 0 or 1
6 Patient has or not has measurable disease
7 Patients written consent to participate in the study has been obtained
8 Latest laboratory values within 14 days prior to enrollment meet all of the following
White blood cell count more than 3000
Platelet count more than 10
Hemoglobin more than 10.0
Total bilirubin less than 1.5
AST less than 100
ALT less than 100
Serum creatinine less than 1.2
SpO2 more than 95
eGFR more than 60

Key exclusion criteria

1. Patient has multiple cancers
2. Patient has active systemic infection
3. Patients who are not willing to use contraception and pregnant and lactating women
4. Psychosis or psychiatric comorbidities
5. History of hypersensitivity to docetaxelcisplatin or polysorbate 80 ontaining products
6. Patient has severe emphysema or pulmonary fibrosis

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Naomi
Middle name
Last name Kiyota

Organization

Kobe University hospital

Division name

Cancer center

Zip code

650-0017

Address

7-5-2, kusunoki-cho, chuo-ku, kobe, hyogo

TEL

078-382-5111

Email

nkiyota@med.kobe-u.ac.jp


Public contact

Name of contact person

1st name Yoshiaki
Middle name
Last name Nagatani

Organization

Kobe University hospital

Division name

Medical oncology and hematology

Zip code

650-0017

Address

7-5-2, kusunoki-cho, chuo-ku, kobe, hyogo

TEL

078-382-5111

Homepage URL


Email

nagatani@med.kobe-u.ac.jp


Sponsor or person

Institute

Kobe University

Institute

Department

Personal name



Funding Source

Organization

Kobe University

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kobe University hospital

Address

7-5-2, kusunoki-cho, chuo-ku, kobe, hyogo

Tel

078-382-6999

Email

kainyu@med.kobe-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

神戸大学医学部附属病院


Other administrative information

Date of disclosure of the study information

2022 Year 09 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2022 Year 05 Month 27 Day

Date of IRB

2022 Year 10 Month 03 Day

Anticipated trial start date

2022 Year 10 Month 03 Day

Last follow-up date

2025 Year 09 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2022 Year 05 Month 27 Day

Last modified on

2022 Year 10 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000054591


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name